Ashton Tweed Connection Vol. 4 No. 1

Featuring CEO Interview with Elizabeth G. Posillico, Ph.D., President & CEO, Elusys Therapeutics Inc.

Your Issue of Ashton Tweed Connection Vol. 4 No. 1 is Here!

Our Site

Contact us

Vol. 4

No. 1

Ashton Tweed can meet your specialized retained search & interim talent needs in the life sciences industry.

CEO Leadership Series: Elizabeth G. Posillico, Ph.D., President & CEO, Elusys Therapeutics, Inc.

During the 11 years that Dr. Elizabeth G. “Tibby” Posillico has been President and CEO of Elusys Therapeutics, Inc., she oversaw the development of a product she hopes no one ever needs…

Read More

Lasting Partnership Expands Corporate Development Team

Lasting Partnership Expands Corp. Dev. Team

A global specialty pharmaceutical company located in Princeton, NJ was looking to expand their corporate development team with a Senior Director of Corporate Development. This client needed help filling this new role because they had very specific requirements of the candidate in order to fit their needs…

The Creation of Ashton Tweed

Since 1982, Jim Rudman, partner and CEO, Ashton Tweed, has held a variety of positions in the staffing industry. Prior to founding Ashton Tweed, he was the vice president of Acsys, Inc. When Acsys was bought in 2004, Rudman decided to leave and do something he had wanted to do for a while – start something on his own…

Don’t miss out
on top hiring news!

Ashton Tweed’s Weekly Digest email covers hiring, firing, & retiring news in the life sciences. Also, check out our:

Featured Candidates

Upcoming Events

Recent Editions

Subscribe Now!

JPM: 100 biopharma execs take gender-diversity pledge

More than 100 biopharma leaders have signed an open letter advocating for the adoption of 10 best practices to increase gender diversity in the industry. MassBio drafted lists of guiding principles and best practices and got biopharma executives…

The 21st Century Cures Act: What You Need to Know

The 21st Century Cures Act is a new law signed into legislation by President Obama that promises to allocate around $6B for funding medical research, the fight against cancer, simplifying drug approvals, mental health issues, and…

Califf to Leave FDA on Inauguration Day

Following tradition, FDA Commissioner Robert Califf will leave the agency on Inauguration Day, on Jan. 20 at noon. Stephen Ostroff, Deputy Commissioner for Foods and Veterinary Medicine, is the next FDA official in line to serve as…

2017 could be pivotal year for CAR-T and CRISPR

2017 is promising to be a pivotal year as CRISPR/Cas9 and CAR-T head toward critical milestones. In the coming months, the first therapy based on CAR-T will likely get regulatory approval, with candidates from Novartis and Kite…

New drug approvals took a nosedive in 2016, here are the 22 that made the grade

In 2016, the FDA approved 22 new drugs, compared with 45 in 2015 and 41 in 2014. Read about the slowdown and see which drugs made the grade…

Read More

New drug approvals took a nosedive in 2016, here are the 22 that made the grade

IBM and Illumina Partner to Standardize Genomic Data Interpretation

IBM Watson Health and Illumina, Inc. announced a partnership to integrate Watson for Genomics into Illumina’s BaseSpace Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and…

IBM and Illumina Partner to Standardize Genomic Data Interpretation

NCI launches new cancer drug formulary to speed combo trials

The National Cancer Institute (NCI) launched a new partnership with the NIH and six pharma companies to speed up clinical trials testing combinations of cancer drugs. Through the new NCI Formulary, Investigators…

NCI launches new cancer drug formulary to speed combo trials

About Ashton Tweed, Ltd.

At the very core of Ashton Tweed’s talent-acquisition and talent-placement business is a robust professional force of highly experienced life sciences industry experts. These uniquely talented professionals are deployed throughout Ashton Tweed’s diverse range of service offerings to solve our clients’ human capital and management needs.